We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Rebuffs Reimbursement of Vertex’s Cystic Fibrosis Drug
NICE Rebuffs Reimbursement of Vertex’s Cystic Fibrosis Drug
The UK’s National Institute for Health and Care Excellence has recommended against reimbursing Vertex Pharmaceuticals’ cystic fibrosis drug Orkambi, saying benefits related to lung function were unlikely to be clinically significant.